Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.
about
An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activityAmino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cellsEstablishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeletonIdentification of APOBEC3DE as another antiretroviral factor from the human APOBEC familyComprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virionsHIV-1 rev depolymerizes microtubules to form stable bilayered ringsProduction of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cellsHow HIV takes advantage of the cytoskeleton in entry and replicationFeline immunodeficiency virus Vif localizes to the nucleusThe inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1.The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.Modulation of the proteome of peripheral blood mononuclear cells from HIV-1-infected patients by drugs of abuse.Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels.Interaction of Theiler's virus with intermediate filaments of infected cellsCellular and viral specificities of human immunodeficiency virus type 1 vif protein.Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded VifVif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.HIV-1 enhances mTORC1 activity and repositions lysosomes to the periphery by co-opting Rag GTPases.Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assemblyUrokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCĪµ.Stably expressed APOBEC3F has negligible antiviral activity.Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function.Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection.The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrestInsights into the dual activity of SIVmac239 Vif against human and African green monkey APOBEC3G.Monomeric APOBEC3G is catalytically active and has antiviral activity.HIV restriction by APOBEC3 in humanized mice.Heroin-Induces Differential Protein Expression by Normal Human Astrocytes (NHA).Characterization of human immunodeficiency virus type 1 Vif particle incorporation.Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins.Roles of the auxiliary genes and AP-1 binding site in the long terminal repeat of feline immunodeficiency virus in the early stage of infection in catsRole of Vif in human immunodeficiency virus type 1 reverse transcriptionThe Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cellsAnalysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virionsHuman immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variantVif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells.
P2860
Q24523705-E893A7C6-6C48-4B86-9DCF-61B3CD4813EDQ24565021-5DF9B96B-E2E7-4F53-B5AC-4C7086CCA2A7Q24599011-730B9370-AC03-4A83-9920-3FF3DA55A804Q24647043-5C6B50C1-9BB1-4CC7-BB3A-EA672525C27BQ24670173-9EAF09FE-0699-4307-9D8A-E9246CFA4DBAQ24678970-3CD135F3-98BE-441C-A631-4AA79F613CEEQ24684972-84759256-EC61-470D-898F-E6D04FE4D355Q24796626-0D13B353-85E2-4943-AEC2-45EF66B3055BQ27021639-222CBD53-1539-420D-A69B-E33ABFF2A7ECQ27469637-3010CBC0-4E8D-4445-B12B-B64CECBDE53DQ30440445-980D0D43-E934-4BF8-8530-225096BBA300Q30860339-C2B9459B-A60A-4FBE-B547-97CF7707C138Q31011512-FD43BE54-6DEA-4C76-A046-B04B3E696982Q33654949-77988D15-CFE6-4571-B2D1-6D49F65C4CC5Q33686493-4F3D1586-F239-46F3-9306-F14CF6359375Q33783386-DFCE5526-41AA-4B62-8257-37EA5B2B8327Q33785960-EDAD6D32-0D7D-4070-A9C0-F05F4D106347Q33806688-D2B21FAD-EB93-4A17-AD6B-284E11EE5182Q33826857-AFCA70F6-71B4-49AB-8580-E456C2CD51D4Q33841920-01F9F899-0B91-4693-B070-783CD9C1D257Q33852465-82CBAFFF-E2E9-4BAD-A3EA-0C04A5EB37A2Q33905696-84F3C590-2341-4149-BF70-602106FAD40EQ33956910-BF05AF33-A9B1-48B1-B166-BEF601D90E9AQ33999971-594DC024-8D91-4C0A-B77B-92427BD7A73BQ34190587-12291B39-C132-4726-8BA2-159A65ECC73AQ34345408-C3374C76-FBE5-4154-8138-E278CCEA1B9EQ34465108-5AC8C705-BAC8-499B-B5E8-62FDC8A90A1EQ34480135-3168CAAE-E36C-4B8E-A0D9-6E559874F86CQ34493717-F14CE4AA-B5B1-4DBA-BBAC-826868F82B77Q34647942-4F228127-6D9D-4BE3-BB0B-CAAAFBEA12CEQ34649651-AC818CCF-C7A7-4458-A193-504FC3C5CB26Q35599877-158D5149-EDAB-4BAA-8FE3-8C54E499DB25Q35868144-D1EEE6C6-107C-464E-85AD-FFE07CF39B24Q35873067-4E4AFDA8-1618-4FE1-A701-A3EF1D11CC1AQ35873443-9AD78117-4E10-469C-9FE6-806AACB28A91Q35873743-CF85CAA8-8532-4CEB-8439-263C127636CEQ35888172-ACF52C82-33AA-4612-866D-CFBB036836DDQ35940059-B82FE786-7928-46BA-996B-1C6D6C44B59EQ35947586-9F8C5DBF-F64C-407F-84D1-9B61C4D8549BQ35947645-F55B440C-9BF0-4A94-8511-F12EFD66CE6B
P2860
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.
description
1996 nĆ® lÅ«n-bĆ»n
@nan
1996 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Õ
ÕøÖÕ¶ÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
1996 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ°ÕøÖÕ¶Õ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
1996幓ć®č«ę
@ja
1996幓č«ę
@yue
1996幓č«ę
@zh-hant
1996幓č«ę
@zh-hk
1996幓č«ę
@zh-mo
1996幓č«ę
@zh-tw
1996幓č®ŗę
@wuu
name
Cytoskeleton association and v ...... ency virus type 1 Vif protein.
@ast
Cytoskeleton association and v ...... ency virus type 1 Vif protein.
@en
Cytoskeleton association and v ...... ency virus type 1 Vif protein.
@nl
type
label
Cytoskeleton association and v ...... ency virus type 1 Vif protein.
@ast
Cytoskeleton association and v ...... ency virus type 1 Vif protein.
@en
Cytoskeleton association and v ...... ency virus type 1 Vif protein.
@nl
prefLabel
Cytoskeleton association and v ...... ency virus type 1 Vif protein.
@ast
Cytoskeleton association and v ...... ency virus type 1 Vif protein.
@en
Cytoskeleton association and v ...... ency virus type 1 Vif protein.
@nl
P2860
P1433
P1476
Cytoskeleton association and v ...... iency virus type 1 Vif protein
@en
P2093
Karczewski MK
P2860
P304
P407
P577
1996-01-01T00:00:00Z